Asset Details
Do you wish to reserve the book?
Synergy and oxygen adaptation for development of next-generation probiotics
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Synergy and oxygen adaptation for development of next-generation probiotics
Do you wish to request the book?
Synergy and oxygen adaptation for development of next-generation probiotics
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Synergy and oxygen adaptation for development of next-generation probiotics
2023
Overview
The human gut microbiota has gained interest as an environmental factor that may contribute to health or disease
1
. The development of next-generation probiotics is a promising strategy to modulate the gut microbiota and improve human health; however, several key candidate next-generation probiotics are strictly anaerobic
2
and may require synergy with other bacteria for optimal growth.
Faecalibacterium prausnitzii
is a highly prevalent and abundant human gut bacterium associated with human health, but it has not yet been developed into probiotic formulations
2
. Here we describe the co-isolation of
F. prausnitzii
and
Desulfovibrio piger
, a sulfate-reducing bacterium, and their cross-feeding for growth and butyrate production. To produce a next-generation probiotic formulation, we adapted
F. prausnitzii
to tolerate oxygen exposure, and, in proof-of-concept studies, we demonstrate that the symbiotic product is tolerated by mice and humans (ClinicalTrials.gov identifier:
NCT03728868
) and is detected in the human gut in a subset of study participants. Our study describes a technology for the production of next-generation probiotics based on the adaptation of strictly anaerobic bacteria to tolerate oxygen exposures without a reduction in potential beneficial properties. Our technology may be used for the development of other strictly anaerobic strains as next-generation probiotics.
The anaerobic gut bacterium
Faecalibacterium prausnitzii
was isolated and adapted for oxygen tolerance to develop a next-generation probiotic for the treatment of conditions such as inflammatory bowel disease and type 2 diabetes.
Publisher
Nature Publishing Group UK,Nature Publishing Group
